TPCW
RARE icon

TD Private Client Wealth’s Ultragenyx Pharmaceutical RARE Stock Holding History

TD Private Client Wealth’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30
Closed -$690 – 1719
2025
Q4 		$690 Hold
30
– – ﹤0.01% 1441
2025
Q3 		$902 Buy
+30
New +$900 ﹤0.01% 1349
2021
Q3 		– Sell
-144
Closed -$13.7K – 1235
2021
Q2 		$13.7K Buy
+144
New +$15K ﹤0.01% 889

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TD Private Client Wealth's RARE Position: Q1 2026 in Review

TD Private Client Wealth sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 30 shares — an estimated $690 sold.

TD Private Client Wealth first reported a position in RARE in Q2 2021 and held it in 3 quarters. The position peaked at $13.7K in Q2 2021. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • TD Private Client Wealth reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • TD Private Client Wealth sold 30 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $690.
  • TD Private Client Wealth first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 3 quarters.
  • TD Private Client Wealth's Ultragenyx Pharmaceutical position peaked at $13.7K in Q2 2021.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.